MediciNova Stock (NASDAQ:MNOV), Trade Ideas

MediciNova

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABTS

AKLI

DRCT

DXYZ

FRGE

HKIT

HOOD

JOAN

LUXH

MESO

MIRA

MNOV

MRDB

NCNO

NUVB

PAYS

PRGS

STKS

Shares of  MariaDB plc  (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company.

Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket

Intraday Update

AIRE

ALUR

ALZN

AUVI

AVXL

BBAR

BRSH

BSFC

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CEPU

CHGG

COIN

CUEN

CYTO

GGAL

GNLX

GTEC

GYRE

IOVA

KRON

LGMK

LOMA

MGOL

MOTS

NSTG

NTLA

PXMD

SGBX

Telecom Argentina Stet - France Telecom S.A.

THAR

TSVT

XPEV

YOSH

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales.

ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million.

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Biotech

Equities

Health Care

General

MediciNova Inc&#39;s (NASDAQ: MNOV) collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the 

Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?

MediciNova Inc

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATNF

CERS

ELTX

ETAO

GOSS

LGVN

SINT

STOK

12 Health Care Stocks Moving In Friday's After-Market Session

Abstract Number:&nbsp;2106
Title:&nbsp; Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)
Session&nbsp;Title: Rapid Oral Abstract &ndash; Central Nervous System Tumors
Session Date:&nbsp;June 2, 2024
Session Time:&nbsp;11:30 AM &ndash; 1:00 PM

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

<h3>Gainers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 24.34% to $3.78. The company's market cap stands at $31.9 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 17.9% to $15.41. The company's market cap stands at $1.6 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares increased by 14.93% to $0.53. The market value of their outstanding shares is at $18.5 million. As per the news, the Q4 earnings report came out today. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares moved upwards by 11.11% to $3.2. The market value of their outstanding shares is at $700.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares rose 10.29% to $1.5. The company's market cap stands at $73.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 20.6% to $0.3 during Wednesday's pre-market session. The company's market cap stands at $23.7 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) stock fell 15.67% to $0.63. The market value of their outstanding shares is at $6.3 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares declined by 14.76% to $3.35. The company's market cap stands at $339.9 million. </li>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) stock declined by 12.72% to $7.55. The market value of their outstanding shares is at $405.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock decreased by 12.68% to $0.53. The company's market cap stands at $23.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares decreased by 12.28% to $3.93. The company's market cap stands at $122.2 million. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LIXT

NTRB

NVCR

OPGN

PDSB

SSKN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of MariaDB plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrdb#NYSE">MRDB</a>) rose sharply in today&rsquo;s pre-market trading after Progress Software (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prgs#NASDAQ">PRGS</a>) announced that it is possibly considering an offer for the company.
MariaDB shares jumped 100.4% to $0.4530 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Destiny Tech100 Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 52.9% to $13.76 in pre-market trading after gaining 9% on Tuesday.</li>
<li>PaySign, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pays#NASDAQ">PAYS</a>) gained 25.2% to $4.23 in pre-market trading after the company announced better-than-expected fourth-quarter results.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) gained 19.1% to $1.69 in pre-market trading.</li>
<li>The ONE Group Hospitality, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stks#NASDAQ">STKS</a>) shares rose 13.2% to $4.54 in pre-market trading after the company announced that it will acquire Safflower Holdings.</li>
<li>nCino, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncno#NASDAQ">NCNO</a>) gained 11.7% to $33.72 in pre-market trading as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..</li>
<li>Nuvation Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NASDAQ">NUVB</a>) shares rose 11.5% to $3.21 in pre-market trading. Nuvation Bio shares gained 28% on Tuesday after BTIG upgraded the stock from Neutral to Buy.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) gained 11.5% to $64.70 in pre-market trading after jumping 16% on Tuesday.</li>
<li>MediciNova, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) climbed 10.2% to $1.50 in pre-market trading. MediciNova received a Notice of Allowance from Japan Patent Office for MN-166 in macular injury treatment.</li>
<li><a href="https://www.benzinga.com/money/robinhood-alternatives/">Robinhood</a> Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) gained 6.3% to $20.50 in pre-market trading. Robinhood launched its Gold Card, offering a 1% boost on Gold deposits and a redesigned app. The announcement was made at its first-ever keynote event.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Direct Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drct#NASDAQ">DRCT</a>) dipped 39.8% to $15.95 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Velo3D, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vld#NYSE">VLD</a>) declined 34.1% to $0.3820 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 30.9% to $0.0760 pre-market trading after dipping over 6% on Tuesday. The Nasdaq recently determined that the company is no longer suitable for listing and its stock will be suspended on March 28.</li>
<li>LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell 20.5% to $1.70 pre-market trading after the company issued preliminary unaudited 2023 fourth quarter and full year financial results.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) shares fell 14.9% to $13.19 in pre-market trading as the company posted weaker-than-expected results for its fourth quarter on Tuesday.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares tumbled 13.6% to $0.3289 in pre-market trading. The company received a notice of allowance for U.S. Patent Application 17/890,478 titled Cognitive Platform For Deriving Effort Metric For Optimizing Cognitive Treatment (Using Data Computed With Artificial Neural Network Or Deep Learning Techniques)</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) fell 12.4% to $2.32 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares dropped 12.1% to $3.45 in pre-market trading. Mesoblast shares jumped over 78% on Tuesday after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) fell 10.4% to $1.03 in pre-market trading.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 7.7% to $0.72 in pre-market trading after gaining 7% on Tuesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37927495/jim-cramer-says-dont-sell-this-beauty-brand-believes-kkr-and-blackstone-can-make-more-mo"> Jim Cramer Says Don&#39;t Sell This Beauty Brand, Believes KKR And Blackstone &#39;Can Make More Money&#39;</a>

Once issued, this patent is expected to expire no earlier than&nbsp;October 2039. &nbsp;The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.&nbsp;

Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment

&nbsp;MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled&nbsp;&quot;STUDY PROTOCOL TO EVALUATE MN-001&#39;S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)&quot;&nbsp;and &quot;MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX&quot; have been accepted and selected for poster presentation at the 92nd&nbsp;European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.

Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress

MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million. </li>
<li>Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million. </li>
<li>Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEAT

BSGM

CDXS

DTIL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JANX

LGND

MDRX

NRXP

TMDX

VKTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock increased by 17.77% to $1.59. The market value of their outstanding shares is at $77.9 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares moved upwards by 14.5% to $143.0. The market value of their outstanding shares is at $13.3 billion. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares rose 12.32% to $1.64. The company's market cap stands at $79.1 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock increased by 11.4% to $0.38. The company's market cap stands at $4.5 million. </li>
<li>Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) stock increased by 10.86% to $20.0. The market value of their outstanding shares is at $820.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares decreased by 8.6% to $3.6 during Friday's pre-market session. The company's market cap stands at $185.9 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 7.67% to $5.9. The company's market cap stands at $23.8 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 7.66% to $2.51. The market value of their outstanding shares is at $10.8 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares fell 7.41% to $2.5. The market value of their outstanding shares is at $10.8 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock decreased by 7.31% to $1.65. The company's market cap stands at $34.8 million. </li>
<li>AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) shares fell 7.26% to $72.0. The market value of their outstanding shares is at $2.7 billion. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AORT

HCTI

HEPA

IKNA

SIEN

SRPT

SXTC

TTOO

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) stock moved upwards by 31.5% to $21.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $729.1 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock moved upwards by 25.75% to $10.45. The company's market cap stands at $1.6 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock rose 21.37% to $1.76. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) stock increased by 21.01% to $1.9. The market value of their outstanding shares is at $25.5 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares rose 17.85% to $1.65. The market value of their outstanding shares is at $35.0 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock moved upwards by 16.91% to $1.59. The market value of their outstanding shares is at $77.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock decreased by 51.3% to $0.29 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) shares fell 43.98% to $2.51. The market value of their outstanding shares is at $130.1 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 17.39% to $0.94. The company's market cap stands at $2.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares fell 12.02% to $2.93. The market value of their outstanding shares is at $18.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 11.17% to $1.91. The market value of their outstanding shares is at $68.0 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock declined by 10.1% to $0.17. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

ENSC

GTHX

ITRM

KALV

MODD

SBFM

SYRA

XAIR

ZJYL

MediciNova Secures Notice Of Grant For New Patent Covering MN-166 (ibudilast) For Treatment Of Macular Injury In China

MediciNova Says Abstract Regarding MN-166 (ibudilast) In Chlorine Gas-induced Lung Injury Accepted For Presentation At The 63rd Annual Meeting Of The Society Of Toxicology

MediciNova Receives Notice Of Decision To Grant For New Patent Covering MN-166 (ibudilast) For Treatment Of Progressive MS In Europe

Shares of ReNew Energy Global Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnw#NASDAQ">RNW</a>) gained during Monday&rsquo;s session following strong quarterly sales.
ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates of $258.41 million.
ReNew Energy raised its FY24 adjusted EBITDA guidance to INR 62 billion - INR 66 billion.
ReNew Energy Global gained 13.6% to $6.74 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Bruush Oral Care Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brsh#NASDAQ">BRSH</a>) shares jumped 147.2% to $0.4179. Br&uuml;ush received Nasdaq notification regarding minimum bid requirements.</li>
<li>Cuentas Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cuen#NASDAQ">CUEN</a>) shares gained 59% to $1.5098 after reporting a narrower quarterly loss.</li>
<li>Altamira Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyto#NASDAQ">CYTO</a>) jumped 52% to $0.4280. Altamira Therapeutics recently entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG.</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdio#NASDAQ">CDIO</a>) gained 41.4% to $1.4000. Cardio Diagnostics Holdings announced the publication of its study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association.</li>
<li>YPF Sociedad An&oacute;nima (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ypf#NYSE">YPF</a>) shares climbed 40.8% to $15.11. Javier Milei&lsquo;s victory in Argentina&rsquo;s presidential election sparked a rally in Argentine ADRs trading on major U.S. stock exchanges.</li>
<li>GD Culture Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdc#NASDAQ">GDC</a>) rose 26.8% to $4.3074. GD Culture Group unveiled its transformative and photorealistic AI-driven digital human technology on TikTok.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) shares gained 26.8% to $0.1752 after jumping 18% on Friday. Blue Star Foods recently signed a 2-year bid award purchase agreement with Sysco Corporation.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) gained 25.3% to $4.2729. MIRA Pharmaceuticals announced exclusive licensing agreement for oral ketamine analog, Ketamir-2.</li>
<li>Grupo Financiero Galicia S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ggal#NASDAQ">GGAL</a>) rose 25% to $15.63 after gaining 5% on Friday.</li>
<li>Transportadora de Gas del Sur S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgs#NYSE">TGS</a>) shares climbed 23.1% to $12.88 after gaining over 4% on Friday.</li>
<li>Central Puerto S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cepu#NYSE">CEPU</a>) climbed 23.1% to $7.58.</li>
<li>Pampa Energ&iacute;a S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pam#NYSE">PAM</a>) gained 23% to $45.60.</li>
<li>Transportadora de Gas del Sur S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgs#NYSE">TGS</a>) rose 22.6% to $12.82 after gaining over 4% on Friday.</li>
<li>Banco BBVA Argentina S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbar#NYSE">BBAR</a>) gained 22.4% to $5.40.</li>
<li>LogicMark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgmk#NASDAQ">LGMK</a>) shares rose 22.2% to $2.04. LogicMark recently posted GAAP loss of $1.10 per share for the third quarter.</li>
<li>IRSA Inversiones y Representaciones Sociedad An&oacute;nima (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/irs#NYSE">IRS</a>) gained 20.3% to $7.79.</li>
<li>Telecom Argentina S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/teo#NYSE">TEO</a>) climbed 19.4% to $6.40 after gaining around 4% on Friday.</li>
<li>Banco Macro S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bma#NYSE">BMA</a>) gained 17.1% to $23.71.</li>
<li>HireRight Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrt#NYSE">HRT</a>) jumped 17.4% to $11.81 after gaining 5% on Friday.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares climbed 15.7% to $0.4050. The company recently reported an increase in quarterly sales.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 15.6% to $17.00.</li>
<li>MediciNova, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) rose 15.2% to $2.0508. The company announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma presented at the 28th Annual Meeting of the Society for Neuro-Oncology.</li>
<li>Kronos Bio, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kron#NASDAQ">KRON</a>) gained 14.4% to $1.2699. Kronos recently posted downbeat quarterly results.</li>
<li>Loma Negra Compa&ntilde;&iacute;a Industrial Argentina Sociedad An&oacute;nima (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/loma#NYSE">LOMA</a>) gained 14.4% to $6.80.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iova#NASDAQ">IOVA</a>) rose 13.6% to $5.74. Goldman Sachs initiated coverage on Iovance Biotherapeutics with a Buy rating and announced a price target of $12.</li>
<li>Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) jumped 11.8% to $7.01. The clinical-stage biopharmaceutical company announced that it initiated a regulatory submission with the European Medicines Agency (EMA).</li>
<li>Intellia Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntla#NASDAQ">NTLA</a>) rose 11.7% to $31.42. Intellia Therapeutics recently announced it received European Union orphan drug designation for NTLA-2002.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) gained 9% to $18.30.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) gained 7.6% to $3.98 after declining around 5% on Friday. Motus GI recently announced the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) fell 6.2% to $7.85. Nio announced on Sunday that it has activated its 2,100th power swap station.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) gained 4.2% to $103.12.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>NanoString Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nstg#NASDAQ">NSTG</a>) shares fell 46% to $0.69. TD Cowen downgraded NanoString Technologies from Outperform to Market Perform and lowered the price target from $6 to $1.4.</li>
<li>PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) fell 40.6% to $1.04 after the company announced pricing of $7 million public offering of 5,384,615 shares and accompanying warrants at a price of $1.30 per unit.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) fell 25.5% to $3.14. Safe And Green Development shares jumped 39% on Friday after the company said it does not intend to conduct the offering of the shares of common stock contemplated by the Registration Statement.</li>
<li>Alzamend Neuro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alzn#NASDAQ">ALZN</a>) dipped 25% to $1.2400. Alzamend Neuro received a &quot;Study May Proceed&quot; letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for major depressive disorder (MDD).</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) fell 24.2% to $0.6559. Yatsen Holding is expected to release its unaudited financial results for the third quarter on Nov. 21, 2023.</li>
<li>2seventy bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsvt#NASDAQ">TSVT</a>) declined 16.4% to $1.78. The FDA&#39;s Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal Phase 3 KarMMa-3 study.</li>
<li>Allurion Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alur#NYSE">ALUR</a>) fell 12.6% to $3.72.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgbx#NASDAQ">SGBX</a>) shares fell 12.6% to $0.6821 after gaining around 7% on Friday. Safe &amp; Green Holdings recently posted a narrower-than-expected quarterly loss.</li>
<li>Greenland Technologies Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtec#NASDAQ">GTEC</a>) declined 12.5% to $2.87 following weak quarterly results.</li>
<li>reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) declined 10.5% to $8.40. ReAlpha Tech filed a prospectus for the offering of up to 1.67 million common units at a price of $12 per unit.</li>
<li>Applied UV, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auvi#NASDAQ">AUVI</a>) shares fell 9.4% to $0.1340 after the company reported third-quarter results.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) shares fell 9.1% to $0.50 after jumping over 10% on Friday. MGO Global recently posted a wider third-quarter loss.</li>
<li>Genelux Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnlx#NASDAQ">GNLX</a>) declined 8.7% to $10.83.</li>
<li>Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares fell 8.6% to $0.1922. Tharimmune shares climbed around 17% on Friday after the company announced a 1-for-25 reverse stock split.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) fell 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price target from $10 to $9.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35870052/this-analyst-with-84-accuracy-rate-sees-around-22-upside-in-nvidia-here-are-5-stock-pick"> This Analyst With 84% Accuracy Rate Sees Around 22% Upside In NVIDIA - Here Are 5 Stock Picks For Last Week From Wall Street&#39;s Most Accurate Analysts</a>

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

MediciNova Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) collaborators presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/11/g35866160/medicinova-announces-new-data-and-results-of-a-phase-2-clinical-trial-of-mn-166-ibudilast-in-gliob" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">Society for Neuro-Oncology</a>.&nbsp;
The primary endpoints of this Phase 2 clinical trial were the safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and efficacy of the combination treatment defined as progression-free survival rate at six months using the RANO criteria.&nbsp;
MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
The highlights of the presentation are as follows:
<ul>
<li>All of the subjects received TMZ and MN-166 (ibudilast) treatment. Progression-free survival at six months was 44% for new GBM and 31% for recurrent GBM.</li>
<li>Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.</li>
<li>CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ, as subjects with progression had higher CD3 tumor infiltration than subjects with no progression (p&lt;0.05)</li>
</ul>
The presentation also included data from preclinical studies that evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
<ul>
<li>Median survival was 17 days for the vehicle and 28 days for the anti-PD1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD1 inhibitor treatment significantly extended survival to a median of 66 days (p&lt;0.001) for the combination therapy.</li>
<li>Median survival was 18 days for the vehicle and 26 days for the anti-PD-L1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days (p&lt;0.05) for the combination therapy.</li>
</ul>
Price Action:&nbsp;MNOV shares are up 14.3% at $2.04 on the last check Monday.
Photo Via Company

WIIM

MediciNova shares are trading higher after the company announced new data and results from its Phase 2 MN-166 trial in glioblastoma.

Shares of Applied UV, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auvi#NASDAQ">AUVI</a>) shares jumped in pre-market trading after the company reported <a href="https://www.benzinga.com/quote/AUVI/earnings">third-quarter results.</a>
Applied UV posted a quarterly loss of 32 cents per share, versus a year-ago loss of $1.20 per share. The company&rsquo;s quarterly sales came in at $11.45 million up from $5.88 million, according to data from <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Applied UV reaffirmed its previous guidance of approximately $45 million in revenue for 2023.
Applied UV shares rose 96.1% to $0.29 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Bruush Oral Care Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brsh#NASDAQ">BRSH</a>) shares rose 172.2% to $0.4601 in pre-market trading. Br&uuml;ush received Nasdaq notification regarding minimum bid requirements.</li>
<li>Blue Star Foods Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsfc#NASDAQ">BSFC</a>) shares surged 82.2% to $0.2526 in pre-market trading after jumping 18% on Friday. Blue Star Foods recently signed a 2-year bid award purchase agreement with Sysco Corporation.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares rose 34.2% to $0.47 in pre-market trading. The company recently reported an increase in quarterly sales.</li>
<li>MediciNova, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) rose 18% to $2.10 in pre-market trading. The company announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma presented at the 28th Annual Meeting of the Society for Neuro-Oncology.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) gained 17.8% to $4.36 in pre-market trading after declining around 5% on Friday. Motus GI recently announced the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.</li>
<li>High Tide Inc.. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hiti#NASDAQ">HITI</a>) shares climbed 16% to $1.38 in pre-market trading after declining around 5% on Friday.</li>
<li>LogicMark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgmk#NASDAQ">LGMK</a>) shares rose 13.8% to $1.90 in pre-market trading. LogicMark recently posted GAAP loss of $1.10 per share for the third quarter.</li>
<li>Transportadora de Gas del Sur S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgs#NYSE">TGS</a>) rose 12.2% to $11.76 in pre-market trading after gaining over 4% on Friday.</li>
<li>Kronos Bio, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kron#NASDAQ">KRON</a>) gained 11.7% to $1.24 in pre-market trading. Kronos recently posted downbeat quarterly results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) dipped 19% to $3.41 in pre-market trading. Safe And Green Development shares jumped 39% on Friday after the company said it does not intend to conduct the offering of the shares of common stock contemplated by the Registration Statement.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlgs#NASDAQ">WLGS</a>) shares fell 19% to $0.6364 in pre-market trading after gaining more than 95% on Friday.</li>
<li>Mural Oncology plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mura#NASDAQ">MURA</a>) fell 17.6% to $4.07 in pre-market after jumping 30% on Friday.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgbx#NASDAQ">SGBX</a>) shares fell 16.6% to $0.6508 in pre-market trading after gaining around 7% on Friday. Safe &amp; Green Holdings recently posted a narrower-than-expected quarterly loss.</li>
<li>Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares fell 16.6% to $0.1750 in pre-market trading. Tharimmune shares climbed around 17% on Friday after the company announced a 1-for-25 reverse stock split.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) shares fell 15.5% to $0.4650 in pre-market trading after jumping over 10% on Friday. MGO Global recently posted a wider third-quarter loss.</li>
<li>Syntec Optics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/optx#NASDAQ">OPTX</a>) fell 14.8% to $7.63 in pre-market trading after jumping 74% on Friday.</li>
<li>Assure Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ionm#NASDAQ">IONM</a>) fell 14.6% to $0.2466 in pre-market trading after declining around 7% on Friday.</li>
<li>Aligos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/algs#NASDAQ">ALGS</a>) shares fell 14% to $0.59 in pre-market trading. Aligos Therapeutics filed prospectus related to resale from time to time of up to 168.7 million shares of common stock, by selling securityholders.</li>
<li>Powerbridge Technologies Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbts#NASDAQ">PBTS</a>) shares fell 9.2% to $0.69 in pre-market trading after jumping 38% on Friday.</li>
</ul>

Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/35867786/agilent-likely-to-report-lower-q4-earnings-heres-a-look-at-recent-price-target-changes-by-the-most-"> Agilent Likely To Report Lower Q4 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

ALGS

HITI

IONM

MURA

OPTX

PBTS

WLGS

Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock rose 27.7% to $0.36 during Monday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock increased by 22.15% to $2.04. The company's market cap stands at $2.8 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock moved upwards by 20.9% to $0.2. The company's market cap stands at $6.3 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock rose 16.29% to $2.07. The market value of their outstanding shares is at $101.5 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock moved upwards by 15.31% to $1.28. The company's market cap stands at $74.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares increased by 14.66% to $0.19. The market value of their outstanding shares is at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares decreased by 30.0% to $0.32 during Monday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares decreased by 22.23% to $0.21. The company's market cap stands at $2.4 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock fell 12.78% to $11.94. The market value of their outstanding shares is at $530.5 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares fell 12.54% to $0.6. The company's market cap stands at $44.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock decreased by 10.66% to $0.55. The company's market cap stands at $1.7 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock fell 10.46% to $0.63. The market value of their outstanding shares is at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

DRMA

HSCS

Intelligent Bio Solutions Inc. - Common Stock

INBS

TCON

VERA

YTEN

12 Health Care Stocks Moving In Monday's Pre-Market Session

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at&nbsp;the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology,&nbsp;Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models. &nbsp;
The primary endpoints of this Phase 2 clinical trial were safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and efficacy of the combination treatment defined as progression-free survival rate at 6 months using the RANO criteria. MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
The highlights of the presentation are as follows:
Phase II clinical trial and immunohistochemistry study
<ul>
<li>The trial enrolled a total of 62 patients, including 36 newly diagnosed GBM (new GBM) patients and 26 recurrent GBM patients
<ul>
<li>Study participants' mean age at screening was 58.9 years old for new GBM and 59.6 years old for recurrent GBM</li>
<li>39% of patients were female in both groups</li>
<li>94% of new GBM patients and 100% of recurrent GBM patients were Caucasian</li>
</ul>
</li>
<li>All of the subjects received TMZ and MN-166 (ibudilast) treatment</li>
<li>Progression-Free Survival at 6 months (PFS6) was 44% for new GBM and 31% for recurrent GBM</li>
<li>Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74
<ul>
<li>CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ as subjects with progression had higher CD3 tumor infiltration than subjects with no progression (p&lt;0.05)</li>
</ul>
</li>
</ul>
Preclinical GBM model studies
<ul>
<li>C57BL/6 mice were intracranially injected with SB28 tumor cells at 4 weeks of life and then treated with either isotype control, vehicle control, MN-166 (ibudilast), anti-PD1, anti-PDL1 or a combination therapy
<ul>
<li>Median survival was 17 days for the vehicle and 28 days for the anti-PD1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD1 inhibitor treatment significantly extended survival to a median of 66 days (p&lt;0.001) for the combination therapy.</li>
<li>Median survival was 18 days for the vehicle and 26 days for the anti-PD-L1 inhibitor treatment alone. The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days (p&lt;0.05) for the combination therapy. &nbsp;</li>
</ul>
</li>
</ul>
Kazuko Matsuda, M.D., Ph.D., M.P.H., Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased to report the positive safety and efficacy results from the first GBM clinical trial of MN-166. GBM's rapid progression and resistance to therapy poses a serious challenge to the medical community. Evaluation of MN-166 (ibudilast) as an adjuvant therapy with TMZ in GBM patients was generally safe and well tolerated. For the PFS6 primary efficacy endpoint, recurrent GBM patients showed a higher PFS6 rate compared to most historical studies. Moreover, the preclinical studies presented at this meeting support our postulation that adding MN-166 (ibudilast) to existing therapies, e.g., TMZ, anti-PD1 or anti-PD-L1, improves survival more than the individual therapies alone. We are excited by the findings presented by our esteemed collaborators and look forward to completing the full data analysis from the GBM clinical trial. We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial. MediciNova is grateful to the patients and families for their invaluable participation in our trial."
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). &nbsp;&nbsp;

MediciNova Announces New Data And Results Of A Phase 2 Clinical Trial Of MN-166 In Glioblastoma Presented At The 28th Annual Meeting Of The Society For Neuro-Oncology

MediciNova's Collaborator Genzyme Initiates Clinical Development Of A Gene Therapy Product For The Treatment Of Phenylketonuria

Fortress Biotech, Plus Therapeutics among healthcare movers

Biggest stock movers today: Boeing, NanoString, NuScale Power, Chegg and more

Medicinova Inc (MNOV) has fallen Tuesday morning, with the stock falling -7.28% in pre-market trading to 1.91. MNOV's short-term technical score of 54 indicates that the stock has traded more bullishly over the last month than 54% of stocks on the market. In the Biotechnology industry, which ranks 124 out of 146 industries

Premarket Mover: Medicinova Inc (MNOV) Down 7.28%

SBSW, LGMK and MNOV among pre-market losers

Medicinova Inc (MNOV) has fallen Wednesday morning, with the stock falling -2.69% in pre-market trading to 1.81. MNOV's short-term technical score of 16 indicates that the stock has traded less bullishly over the last month than 84% of stocks on the market. In the Biotechnology industry, which ranks 130 out of 146 industri

Premarket Mover: Medicinova Inc (MNOV) Down 2.69%

Medicinova Inc (MNOV) is up Friday morning, with the stock adding 5.41% in pre-market trading to 1.56. MNOV's short-term technical score of 9 indicates that the stock has traded less bullishly over the last month than 91% of stocks on the market. In the Biotechnology industry, which ranks 126 out of 146 industries, MNOV ra

Should You Hold Medicinova Inc (MNOV) Stock Friday Morning?

Medicinova Inc (MNOV) is down Tuesday morning, with the stock losing -5.15% in pre-market trading to 1.29. MNOV's short-term technical score of 2 indicates that the stock has traded less bullishly over the last month than 98% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, Med

Should You Hold Medicinova Inc (MNOV) Stock Tuesday Morning?

Medicinova Inc (MNOV) is up Wednesday morning, with the stock gaining 11.03% in pre-market trading to 1.51. MNOV's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 100 out of 146 industries, M

Should You Sell Medicinova Inc (MNOV) Stock Wednesday Morning?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news!



We&rsquo;re seeing lots of earnings reports and acquisition deals moving stocks this morning.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MariaDB (NYSE:<a href="https://investorplace.com/stock-quotes/mrdb-stock-quote/">MRDB</a>) stock is rocketing 88% higher after Progress Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/prgs-stock-quote/">PRGS</a>) confirmed its <a href="https://www.globenewswire.com/news-release/2024/03/26/2852748/0/en/Progress-Software-Corp-Statement-regarding-Possible-Offer-for-MariaDB-plc.html">considering an offer for the company</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are soaring more than 51% <a href="https://finance.yahoo.com/news/destiny-tech100-dxyz-list-york-130000099.html">after going public yesterday</a>.</li>



<li>PaySign (NASDAQ:<a href="https://investorplace.com/stock-quotes/pays-stock-quote/">PAYS</a>) stock is surging close to 24% after <a href="https://www.nasdaq.com/articles/paysign-q4-results-top-estimates-stock-up">beating Q4 estimates</a>.</li>



<li>Hitek Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/hkit-stock-quote/">HKIT</a>) shares are gaining over 19% without any clear news this morning.</li>



<li>The One Group Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/stks-stock-quote/">STKS</a>) stock is increasing more than 14% on news of <a href="https://www.nasdaq.com/press-release/the-one-group-hospitality-inc.-to-acquire-owner-of-benihana-2024-03-26">an acquisition deal</a>.</li>



<li>Ncino (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncno-stock-quote/">NCNO</a>) shares are rising over 14% after releasing <a href="https://finance.yahoo.com/news/ncino-inc-ncno-posts-strong-213133132.html">strong 2024 earnings</a>.</li>



<li>Trump Media &amp; Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/djt-stock-quote/">DJT</a>) stock is climbing more than 13% following its <a href="https://www.cnbc.com/2024/03/26/trump-media-stock-ticker-djt-debuts-after-dwac-merger.html">public debut yesterday</a>.</li>



<li>Nuvation Bio (NYSE:<a href="https://investorplace.com/stock-quotes/nuvb-stock-quote/">NUVB</a>) shares are heading over 12% higher after <a href="https://finance.yahoo.com/news/nuvation-bio-acquire-anheart-therapeutics-110000998.html">announcing an acquisition deal</a>.</li>



<li>Cazoo (NYSE:<a href="https://investorplace.com/stock-quotes/czoo-stock-quote/">CZOO</a>) stock is jumping more than 11% this morning.</li>



<li>MediciNova (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnov-stock-quote/">MNOV</a>) shares are up over 11% after <a href="https://www.nasdaq.com/press-release/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-166-ibudilast">getting a new patent</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Direct Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/drct-stock-quote/">DRCT</a>) stock is plummeting more than 42% after <a href="https://www.nasdaq.com/press-release/direct-digital-holdings-reports-q4-full-year-2023-results-2024-03-26">missing estimates in Q4 2023</a>.</li>



<li>Velo3D (NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/">VLD</a>) shares are diving over 30% with the release of its <a href="https://finance.yahoo.com/news/velo3d-announces-fourth-quarter-fiscal-200500348.html">latest earnings report</a>.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) stock is taking a more than 20% beating after <a href="https://www.barrons.com/articles/gamestop-earnings-stock-price-489eef2e">posting an earnings miss</a>.</li>



<li>Akili (NASDAQ:<a href="https://investorplace.com/stock-quotes/akli-stock-quote/">AKLI</a>) shares are sliding over 19% despite a lack of news this morning.</li>



<li>Joann (NASDAQ:<a href="https://investorplace.com/stock-quotes/joan-stock-quote/">JOAN</a>) stock is tumbling more than 19% <a href="https://investorplace.com/2024/03/dear-joan-stock-fans-brace-for-a-suspension-on-march-28/">ahead of its stock suspension</a>.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are decreasing over 13% after <a href="https://finance.yahoo.com/news/luxurban-hotels-inc-provides-preliminary-212900865.html">releasing Q4 results</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) stock is declining more than 13% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318185982&amp;type=PDF&amp;symbol=QH&amp;cdn=74020f560df9ce8a2a4a9de29c3572f6&amp;companyName=Quhuo+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-03-26">new used-car trading platform</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are slipping over 13% this morning.</li>



<li>Forge Global (NYSE:<a href="https://investorplace.com/stock-quotes/frge-stock-quote/">FRGE</a>) stock is dipping more than 12% on <a href="https://www.marketwatch.com/story/forge-global-shares-sink-after-lower-than-expected-4q-sales-4a3d009d">lagging Q4 sales</a>.</li>



<li>Rubicon Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/rbt-stock-quote/">RBT</a>) shares close out our pre-market stock movers down over 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-march-27th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Medicinova (MNOV) has shared an announcement. Geoffrey O'Brien will retire and step down from his role as Vice President at MediciNova, Inc. on Apr...

MediciNova Vice President Geoffrey O'Brien Announces Retirement

CZOO

FBIO

PENN

PROK

PSTV

SBSW

Press Releases

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Opinion

Thinking about buying stock in Macy's, Marathon Digital, Medicinova, Telecom Argentina, or Nuscale Power?

Legal

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan